1) Kasai K, Ushio A, Kasai Y, et al. Therapeutic efficacy of combination therapy with intra-ar-terial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellu-lar carcinoma with portal venous invasion. Cancer. 2011.
2) Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med . 2008; 359: 378 - 390.
3) Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205 - 216.
4) Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002; 94: 435 - 442.
5) Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006; 106: 1990 - 1997.